부산대학교 도서관

Wisniewska, M; Bossenmaier, B; Georges, G; Hesse, F; Dangl, M; Kunkele, KP; Ioannidis, I; Huber, R; Engh, RA

JOURNAL OF MOLECULAR BIOLOGY; APR 15 2005, 347 5, p1005-p1014, 10p.

Breitenlechner, CB; Friebe, WG; Brunet, E; Guido, W; Graul, M; Thomas, U; Kunkele, KP; Schafer, W; Gassel, M; Bosseineyer, D; Huber, R; Engh, RA; Masjost, B

JOURNAL OF MEDICINAL CHEMISTRY; JAN 13 2005, 48 1, p163-p170, 8p.

Klein, C; Planker, E; Diercks, T; Kessler, H; Kunkele, KP; Lang, K; Hansen, S; Schwaiger, M

JOURNAL OF BIOLOGICAL CHEMISTRY; DEC 28 2001, 276 52, p49020-p49027, 8p.

Dembowski, M; Kunkele, KP; Nargang, FE; Neupert, W; Rapaport, D

JOURNAL OF BIOLOGICAL CHEMISTRY; MAY 25 2001, 276 21, p17679-p17685, 7p.

Stan, T; Ahting, U; Dembowski, M; Kunkele, KP; Nussberger, S; Neupert, W; Rapaport, D

EMBO JOURNAL; SEP 15 2000, 19 18, p4895-p4902, 8p.

Oberg HH; Institute of Immunology, University Hospital Schleswig-Holstein, Kiel, Germany.; Deseke M; Evobright GmbH, Vienna, Austria.; Krohn S; Division of Antibody-Based Immunotherapy, University Hospital Schleswig-Holstein and Christian-Albrechts University, Kiel, Germany.; Winterberg D; Division of Antibody-Based Immunotherapy, University Hospital Schleswig-Holstein and Christian-Albrechts University, Kiel, Germany.; Peipp M; Division of Antibody-Based Immunotherapy, University Hospital Schleswig-Holstein and Christian-Albrechts University, Kiel, Germany.; Bauerschlag D; Polyclinic and Clinic of Gynecology, University Center, Jena, Germany.; Künkele KP; Evobright GmbH, Vienna, Austria.; Wesch D; Institute of Immunology, University Hospital Schleswig-Holstein, Kiel, Germany.; Baumann C; Evobright GmbH, Vienna, Austria.

Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE; In Process

Oberg HH; Institute of Immunology, University Hospital Schleswig-Holstein, Kiel, Germany.; Deseke M; Evobright GmbH, Vienna, Austria.; Krohn S; Division of Antibody-Based Immunotherapy, University Hospital Schleswig-Holstein and Christian-Albrechts University, Kiel, Germany.; Winterberg D; Division of Antibody-Based Immunotherapy, University Hospital Schleswig-Holstein and Christian-Albrechts University, Kiel, Germany.; Peipp M; Division of Antibody-Based Immunotherapy, University Hospital Schleswig-Holstein and Christian-Albrechts University, Kiel, Germany.; Bauerschlag D; Polyclinic and Clinic of Gynecology, University Center, Jena, Germany.; Künkele KP; Evobright GmbH, Vienna, Austria.; Wesch D; Institute of Immunology, University Hospital Schleswig-Holstein, Kiel, Germany.; Baumann C; Evobright GmbH, Vienna, Austria.

Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE

Sustmann C; Roche Pharma Research and Early Development (pRED), Large Molecule Research (LMR), Roche Innovation Center Munich , Penzberg , Germany.; Dickopf S; Roche Pharma Research and Early Development (pRED), Large Molecule Research (LMR), Roche Innovation Center Munich , Penzberg , Germany.; Regula JT; Roche Pharma Research and Early Development (pRED), Large Molecule Research (LMR), Roche Innovation Center Munich , Penzberg , Germany.; Kettenberger H; Roche Pharma Research and Early Development (pRED), Large Molecule Research (LMR), Roche Innovation Center Munich , Penzberg , Germany.; Mølhøj M; Roche Pharma Research and Early Development (pRED), Large Molecule Research (LMR), Roche Innovation Center Munich , Penzberg , Germany.; Gassner C; Roche Pharma Research and Early Development (pRED), Large Molecule Research (LMR), Roche Innovation Center Munich , Penzberg , Germany.; Weininger D; Roche Pharma Research and Early Development (pRED), Large Molecule Research (LMR), Roche Innovation Center Munich , Penzberg , Germany.; Fenn S; Roche Pharma Research and Early Development (pRED), Large Molecule Research (LMR), Roche Innovation Center Munich , Penzberg , Germany.; Manigold T; Roche Pharma Research and Early Development (pRED), Discovery Oncology, Roche Innovation Center Basel , Basel , Switzerland.; Kling L; Roche Pharma Research and Early Development (pRED), Large Molecule Research (LMR), Roche Innovation Center Munich , Penzberg , Germany.; Künkele KP; Roche Pharma Research and Early Development (pRED), Large Molecule Research (LMR), Roche Innovation Center Munich , Penzberg , Germany.; Schwaiger M; Roche Pharma Research and Early Development (pRED), Discovery Oncology, Roche Innovation Center Basel , Basel , Switzerland.; Bossenmaier B; Roche Pharma Research and Early Development (pRED), Large Molecule Research (LMR), Roche Innovation Center Munich , Penzberg , Germany.; Griese JJ; Gene Center and Department of Biochemistry, Ludwig-Maximilians-University , Munich , Germany.; Hopfner KP; Gene Center and Department of Biochemistry, Ludwig-Maximilians-University , Munich , Germany.; Graff-Meyer A; Center for Cellular Imaging and Nanoanalytics, Biozentrum, University of Basel , Basel , Switzerland.; Stahlberg H; Center for Cellular Imaging and Nanoanalytics, Biozentrum, University of Basel , Basel , Switzerland.; Ringler P; Center for Cellular Imaging and Nanoanalytics, Biozentrum, University of Basel , Basel , Switzerland.; Lauer ME; Roche Pharma Research and Early Development (pRED), Small Molecule Research, Roche Innovation Center Basel , Basel , Switzerland.; Brinkmann U; Roche Pharma Research and Early Development (pRED), Large Molecule Research (LMR), Roche Innovation Center Munich , Penzberg , Germany.; Schaefer W; Roche Pharma Research and Early Development (pRED), Large Molecule Research (LMR), Roche Innovation Center Munich , Penzberg , Germany.; Klein C; Roche Pharma Research and Early Development (pRED), Discovery Oncology, Roche Innovation Center Zurich , Schlieren , Switzerland.

Publisher: Taylor & Francis Country of Publication: United States NLM ID: 101479829 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1942-0870 (Electronic) Linking ISSN: 19420862 NLM ISO Abbreviation: MAbs Subsets: MEDLINE

Hofmann I; Cancer Immunology and Immune Modulation (I.H., C.R.-V., M.S.), Cancer Pharmacology and Disease Positioning (A.B., M.H.H., M.A., F.E., F.H.), Cancer Research (D.E., A.G., N.K., K.-P.K.), and Oncology Translational Sciences (F.T., N.B., N.S.), Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria; and Ablynx NV, Ghent/Zwijnaarde, Belgium (E.D., J.B.) irmgard.hofmann@boehringer-ingelheim.com.; Baum A; Cancer Immunology and Immune Modulation (I.H., C.R.-V., M.S.), Cancer Pharmacology and Disease Positioning (A.B., M.H.H., M.A., F.E., F.H.), Cancer Research (D.E., A.G., N.K., K.-P.K.), and Oncology Translational Sciences (F.T., N.B., N.S.), Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria; and Ablynx NV, Ghent/Zwijnaarde, Belgium (E.D., J.B.).; Hofmann MH; Cancer Immunology and Immune Modulation (I.H., C.R.-V., M.S.), Cancer Pharmacology and Disease Positioning (A.B., M.H.H., M.A., F.E., F.H.), Cancer Research (D.E., A.G., N.K., K.-P.K.), and Oncology Translational Sciences (F.T., N.B., N.S.), Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria; and Ablynx NV, Ghent/Zwijnaarde, Belgium (E.D., J.B.).; Trapani F; Cancer Immunology and Immune Modulation (I.H., C.R.-V., M.S.), Cancer Pharmacology and Disease Positioning (A.B., M.H.H., M.A., F.E., F.H.), Cancer Research (D.E., A.G., N.K., K.-P.K.), and Oncology Translational Sciences (F.T., N.B., N.S.), Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria; and Ablynx NV, Ghent/Zwijnaarde, Belgium (E.D., J.B.).; Reichel-Voda C; Cancer Immunology and Immune Modulation (I.H., C.R.-V., M.S.), Cancer Pharmacology and Disease Positioning (A.B., M.H.H., M.A., F.E., F.H.), Cancer Research (D.E., A.G., N.K., K.-P.K.), and Oncology Translational Sciences (F.T., N.B., N.S.), Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria; and Ablynx NV, Ghent/Zwijnaarde, Belgium (E.D., J.B.).; Ehrensperger D; Cancer Immunology and Immune Modulation (I.H., C.R.-V., M.S.), Cancer Pharmacology and Disease Positioning (A.B., M.H.H., M.A., F.E., F.H.), Cancer Research (D.E., A.G., N.K., K.-P.K.), and Oncology Translational Sciences (F.T., N.B., N.S.), Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria; and Ablynx NV, Ghent/Zwijnaarde, Belgium (E.D., J.B.).; Aichinger M; Cancer Immunology and Immune Modulation (I.H., C.R.-V., M.S.), Cancer Pharmacology and Disease Positioning (A.B., M.H.H., M.A., F.E., F.H.), Cancer Research (D.E., A.G., N.K., K.-P.K.), and Oncology Translational Sciences (F.T., N.B., N.S.), Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria; and Ablynx NV, Ghent/Zwijnaarde, Belgium (E.D., J.B.).; Ebner F; Cancer Immunology and Immune Modulation (I.H., C.R.-V., M.S.), Cancer Pharmacology and Disease Positioning (A.B., M.H.H., M.A., F.E., F.H.), Cancer Research (D.E., A.G., N.K., K.-P.K.), and Oncology Translational Sciences (F.T., N.B., N.S.), Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria; and Ablynx NV, Ghent/Zwijnaarde, Belgium (E.D., J.B.).; Budano N; Cancer Immunology and Immune Modulation (I.H., C.R.-V., M.S.), Cancer Pharmacology and Disease Positioning (A.B., M.H.H., M.A., F.E., F.H.), Cancer Research (D.E., A.G., N.K., K.-P.K.), and Oncology Translational Sciences (F.T., N.B., N.S.), Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria; and Ablynx NV, Ghent/Zwijnaarde, Belgium (E.D., J.B.).; Schweifer N; Cancer Immunology and Immune Modulation (I.H., C.R.-V., M.S.), Cancer Pharmacology and Disease Positioning (A.B., M.H.H., M.A., F.E., F.H.), Cancer Research (D.E., A.G., N.K., K.-P.K.), and Oncology Translational Sciences (F.T., N.B., N.S.), Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria; and Ablynx NV, Ghent/Zwijnaarde, Belgium (E.D., J.B.).; Sykora M; Cancer Immunology and Immune Modulation (I.H., C.R.-V., M.S.), Cancer Pharmacology and Disease Positioning (A.B., M.H.H., M.A., F.E., F.H.), Cancer Research (D.E., A.G., N.K., K.-P.K.), and Oncology Translational Sciences (F.T., N.B., N.S.), Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria; and Ablynx NV, Ghent/Zwijnaarde, Belgium (E.D., J.B.).; Depla E; Cancer Immunology and Immune Modulation (I.H., C.R.-V., M.S.), Cancer Pharmacology and Disease Positioning (A.B., M.H.H., M.A., F.E., F.H.), Cancer Research (D.E., A.G., N.K., K.-P.K.), and Oncology Translational Sciences (F.T., N.B., N.S.), Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria; and Ablynx NV, Ghent/Zwijnaarde, Belgium (E.D., J.B.).; Boucneau J; Cancer Immunology and Immune Modulation (I.H., C.R.-V., M.S.), Cancer Pharmacology and Disease Positioning (A.B., M.H.H., M.A., F.E., F.H.), Cancer Research (D.E., A.G., N.K., K.-P.K.), and Oncology Translational Sciences (F.T., N.B., N.S.), Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria; and Ablynx NV, Ghent/Zwijnaarde, Belgium (E.D., J.B.).; Gschwind A; Cancer Immunology and Immune Modulation (I.H., C.R.-V., M.S.), Cancer Pharmacology and Disease Positioning (A.B., M.H.H., M.A., F.E., F.H.), Cancer Research (D.E., A.G., N.K., K.-P.K.), and Oncology Translational Sciences (F.T., N.B., N.S.), Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria; and Ablynx NV, Ghent/Zwijnaarde, Belgium (E.D., J.B.).; Kraut N; Cancer Immunology and Immune Modulation (I.H., C.R.-V., M.S.), Cancer Pharmacology and Disease Positioning (A.B., M.H.H., M.A., F.E., F.H.), Cancer Research (D.E., A.G., N.K., K.-P.K.), and Oncology Translational Sciences (F.T., N.B., N.S.), Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria; and Ablynx NV, Ghent/Zwijnaarde, Belgium (E.D., J.B.).; Hilberg F; Cancer Immunology and Immune Modulation (I.H., C.R.-V., M.S.), Cancer Pharmacology and Disease Positioning (A.B., M.H.H., M.A., F.E., F.H.), Cancer Research (D.E., A.G., N.K., K.-P.K.), and Oncology Translational Sciences (F.T., N.B., N.S.), Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria; and Ablynx NV, Ghent/Zwijnaarde, Belgium (E.D., J.B.).; Künkele KP; Cancer Immunology and Immune Modulation (I.H., C.R.-V., M.S.), Cancer Pharmacology and Disease Positioning (A.B., M.H.H., M.A., F.E., F.H.), Cancer Research (D.E., A.G., N.K., K.-P.K.), and Oncology Translational Sciences (F.T., N.B., N.S.), Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria; and Ablynx NV, Ghent/Zwijnaarde, Belgium (E.D., J.B.).

Publisher: Elsevier Country of Publication: Netherlands NLM ID: 0376362 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1521-0103 (Electronic) Linking ISSN: 00223565 NLM ISO Abbreviation: J Pharmacol Exp Ther Subsets: MEDLINE

Künkele KP; Boehringer Ingelheim RCV GmbH & Co KG, 1121 Vienna, Austria.; Wesch D; Institute of Immunology, University Hospital Schleswig-Holstein, Christian-Albrechts University of Kiel, 24105 Kiel, Germany.; Oberg HH; Institute of Immunology, University Hospital Schleswig-Holstein, Christian-Albrechts University of Kiel, 24105 Kiel, Germany.; Aichinger M; Boehringer Ingelheim RCV GmbH & Co KG, 1121 Vienna, Austria.; Supper V; Boehringer Ingelheim RCV GmbH & Co KG, 1121 Vienna, Austria.; Baumann C; Boehringer Ingelheim RCV GmbH & Co KG, 1121 Vienna, Austria.

Publisher: MDPI Country of Publication: Switzerland NLM ID: 101600052 Publication Model: Electronic Cited Medium: Internet ISSN: 2073-4409 (Electronic) Linking ISSN: 20734409 NLM ISO Abbreviation: Cells Subsets: MEDLINE

Schanzer JM; From Discovery Oncology and juergen_michael.schanzer@roche.com.; Wartha K; From Discovery Oncology and.; Croasdale R; From Discovery Oncology and.; Moser S; Roche Glycart AG, CH-8952 Schlieren, Switzerland, and.; Künkele KP; Boehringer Ingelheim, A-1121 Vienna, Austria.; Ries C; From Discovery Oncology and.; Scheuer W; From Discovery Oncology and.; Duerr H; Large Molecule Research, Pharmaceutical Research and Early Development, Roche Diagnostics GmbH, Nonnenwald 2, D-82372 Penzberg, Germany.; Pompiati S; Large Molecule Research, Pharmaceutical Research and Early Development, Roche Diagnostics GmbH, Nonnenwald 2, D-82372 Penzberg, Germany.; Pollman J; Large Molecule Research, Pharmaceutical Research and Early Development, Roche Diagnostics GmbH, Nonnenwald 2, D-82372 Penzberg, Germany.; Stracke J; Large Molecule Research, Pharmaceutical Research and Early Development, Roche Diagnostics GmbH, Nonnenwald 2, D-82372 Penzberg, Germany.; Lau W; Large Molecule Research, Pharmaceutical Research and Early Development, Roche Diagnostics GmbH, Nonnenwald 2, D-82372 Penzberg, Germany.; Ries S; Large Molecule Research, Pharmaceutical Research and Early Development, Roche Diagnostics GmbH, Nonnenwald 2, D-82372 Penzberg, Germany.; Brinkmann U; Large Molecule Research, Pharmaceutical Research and Early Development, Roche Diagnostics GmbH, Nonnenwald 2, D-82372 Penzberg, Germany.; Klein C; Roche Glycart AG, CH-8952 Schlieren, Switzerland, and.; Umana P; Roche Glycart AG, CH-8952 Schlieren, Switzerland, and.

Publisher: Elsevier Inc. on behalf of American Society for Biochemistry and Molecular Biology Country of Publication: United States NLM ID: 2985121R Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1083-351X (Electronic) Linking ISSN: 00219258 NLM ISO Abbreviation: J Biol Chem Subsets: MEDLINE

Beuger V; Roche Diagnostics GmbH, Nonnenwald 2, 82372 Penzberg, Federal Republic of Germany.; Künkele KP; Koll H; Gärtner A; Bähner M; Burtscher H; Klein C

Publisher: Wiley-Blackwell Country of Publication: United States NLM ID: 8609465 Publication Model: Print Cited Medium: Internet ISSN: 1470-8744 (Electronic) Linking ISSN: 08854513 NLM ISO Abbreviation: Biotechnol Appl Biochem Subsets: MEDLINE

Lühe A; F. Hoffmann-La Roche Ltd., Non-Clinical Drug Safety, CH-4070 Basel, Switzerland. anke.luehe@roche.com ; Künkele KP; Haiker M; Schad K; Zihlmann C; Bauss F; Suter L; Pfister T

Publisher: Pergamon Press Country of Publication: England NLM ID: 8712158 Publication Model: Print-Electronic Cited Medium: Print ISSN: 0887-2333 (Print) Linking ISSN: 08872333 NLM ISO Abbreviation: Toxicol In Vitro Subsets: MEDLINE

Klein C; Pharma Research, Roche Diagnostics GmbH, D-82372 Penzberg, Germany. christian.klein.ck1@roche.com; Georges G; Künkele KP; Huber R; Engh RA; Hansen S

Publisher: Elsevier Inc. on behalf of American Society for Biochemistry and Molecular Biology Country of Publication: United States NLM ID: 2985121R Publication Model: Print-Electronic Cited Medium: Print ISSN: 0021-9258 (Print) Linking ISSN: 00219258 NLM ISO Abbreviation: J Biol Chem Subsets: MEDLINE

Künkele KP; Institut für Physiologische Chemie, Physikalische Biochemie und Zellbiologie der Universität München, Goethestrasse 33, 80336 Munich, Federal Republic of Germany.; Juin P; Pompa C; Nargang FE; Henry JP; Neupert W; Lill R; Thieffry M

Publisher: Elsevier Inc. on behalf of American Society for Biochemistry and Molecular Biology Country of Publication: United States NLM ID: 2985121R Publication Model: Print Cited Medium: Print ISSN: 0021-9258 (Print) Linking ISSN: 00219258 NLM ISO Abbreviation: J Biol Chem Subsets: MEDLINE

Rapaport D; Institut für Physiologische Chemie, Physikalische Biochemie und Zellbiologie der Universität München, 80336 Munich, Germany.; Künkele KP; Dembowski M; Ahting U; Nargang FE; Neupert W; Lill R

Publisher: Taylor & Francis Country of Publication: United States NLM ID: 8109087 Publication Model: Print Cited Medium: Print ISSN: 0270-7306 (Print) Linking ISSN: 02707306 NLM ISO Abbreviation: Mol Cell Biol Subsets: MEDLINE

Künkele KP; Institut für Physiologische Chemie, Physikalische Biochemie, und Zellbiologie der Universität München, Germany.; Heins S; Dembowski M; Nargang FE; Benz R; Thieffry M; Walz J; Lill R; Nussberger S; Neupert W

Publisher: Cell Press Country of Publication: United States NLM ID: 0413066 Publication Model: Print Cited Medium: Print ISSN: 0092-8674 (Print) Linking ISSN: 00928674 NLM ISO Abbreviation: Cell Subsets: MEDLINE

Nargang FE; Department of Biological Sciences, University of Alberta, Edmonton, Canada.; Künkele KP; Mayer A; Ritzel RG; Neupert W; Lill R

Publisher: Nature Publishing Group Country of Publication: England NLM ID: 8208664 Publication Model: Print Cited Medium: Print ISSN: 0261-4189 (Print) Linking ISSN: 02614189 NLM ISO Abbreviation: EMBO J Subsets: MEDLINE

Ridder R; Deutsches Krebsforschungszentrum, Projektgruppe Molekularbiologie der Alterungsprozesse, Heidelberg, Federal Republic of Germany.; Künkele KP; Osiewacz HD

Publisher: Springer International Country of Publication: United States NLM ID: 8004904 Publication Model: Print Cited Medium: Print ISSN: 0172-8083 (Print) Linking ISSN: 01728083 NLM ISO Abbreviation: Curr Genet Subsets: MEDLINE